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ABSTRACT Over a million prosthetic joints are placed in patients in the United States annually. Of those that fail, 25% will be
due to infection, with an estimated cost approaching 1 billion dollars. Despite the clinical and economic importance of these in-
fections, the techniques for their detection are relatively insensitive. An innovative method for detecting these infections by us-
ing blood culture bottles (BCB) to culture specimens of periprosthetic tissue (PPT) was described in a recent article [T. N. Peel, et
al., mBio 7(1):e01776-15, 2016, doi:10.1128/mBio.01776-15]. There are two potential stumbling blocks to the widespread imple-
mentation of this innovation. First, the FDA judges such an application of BCB as an “off-label use” and as such, a laboratory-
developed test (LDT). LDTs are coming under greater scrutiny by the FDA and may require extensive, costly validation studies in
laboratories that adopt this methodology. Second, the Center for Medicare and Medicaid Services has established a Hospital Ac-
quired Condition Reduction Act under which institutions performing in the lowest quartile forfeit 1% of their Medicare reim-
bursement. Hospital-acquired infections are an important component of this quality metric. Although prosthetic joint infection
(PJI) rates are not currently a hospital quality metric, given their cost and increasing frequency, it is reasonable to expect that
they may become one. Will those with financial oversight allow an innovative technique that will require an expensive validation
and may put the institution at risk for loss of CMS reimbursement?
Currently, close to a million joint replacements are performedannually in theUnited States (1). As the population ages in the
industrialized world, it is estimated that the number of joint re-
placements will increase by three- to fivefold over the next two
decades (1). A common complication of this surgery is infections
due to biofilm-producing organisms (1). These infections occur in
1 to 2% of these patients and are estimated to cause as many as
25%of prosthetic joint revisions (1, 2). This number appears to be
increasing, in part because two risk factors for prosthetic joint
infections (PJI), obesity and diabetes, are increasing (1, 2). One of
the challenges faced by clinicians caring for these patients is that a
significant number of patients with clinical and laboratory signs of
infection do have not organisms detected by culture (1, 3).
In 2007, aMayoClinic research group led by R. Patel published
a landmark paper (4) in which they described a novel technique
that used vortexing and sonication of a removed prosthesis as a
means to diagnose PJI. This method proved significantly more
sensitive than the standard culture techniques commonly used at
that time, although more than 20% of specimens from patients
with clinical signs of infection remained culture negative. A partial
explanation for this insensitivity was the observation that at least
some patients had received antimicrobials in the two weeks prior
to culture. Despite its enhanced sensitivity and excellent specific-
ity, this method has not been widely adopted because of its com-
plexity and equipment requirements.
Over the past decade, theMayo group has continued to explore
both conventional and molecular methods as a means of enhanc-
ing the detection of PJI. Surprisingly, in many cases, molecular
methods have not proven to provide a significance advance in PJI
detection (5). There are apparently three problems with these
methods. Sanger-based sequencing of broad-range targets, such as
the 16S rRNA gene, cannot be used for mixed infections and also
require extremely stringent collection techniques to avoid con-
tamination. Next-generation sequencing, while promising, is ex-
pensive, requires significant technical and bioinformatics exper-
tise, and is impractical for most clinical laboratories. Multiplex
assays for the detection of potential PJI pathogens are the most
promising approach but are challenging due to the breadth of
organisms that could be either pathogens or contaminating flora.
The clinical sensitivity and specificity of these assays still need
optimization before routine implementation.
The latest innovation by the Mayo group is described in a re-
cent article in mBio (6). In this study, they extend two previous
studies using blood culture bottles (BCB) for the detection of PJI
(7, 8). The method described is to culture periprosthetic tissue
(PPT) that has been processed using a Stomacher device. This
process is believed to release organisms from tissue, including
those growing in biofilms, but does not lyse them.Onemilliliter of
fluid is then added to both an aerobic and an anaerobic BCB and
cultured for either 7 (aerobic) or 14 days (anaerobic). The authors
applied a novel statistical method, Bayesian latent class modeling
(LCM), to judge the sensitivity and specificity of this novel BCB
approach in comparison to those of standard agar and broth PPT
cultures. They also compared the different culture methods to the
IDSA PJI criteria. Using the Bayesian LCM method, the authors
found the BCB method to be more sensitive and specific than
standard PPTmethods. When using the IDSA criteria as the diag-
nostic truth, both culture methods proved less sensitive but had
similar specificity, although the BCB method had superior sensi-
tivity. The BCB-based method has two distinct advantages over
the standard culture methods. First, the time to organism detec-
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tion is decreased, although howmuch this would improve clinical
outcomes is unclear. Second, the method allows automated mon-
itoring of the culture, making this method much less labor inten-
sive after the initial processing, which would be essentially the
same for the methods being compared.
While the authors are commended for applying a routine,
widely available culture method (blood culture bottles) to a new
specimen type to increase sensitivity and time to result, this ap-
proach presents challenges formany laboratories. The inoculation
of PPT intoBCB is considered an “off-label” use of BCBs,meaning
it is not FDA-approved/cleared. As such, clinical laboratories
must undergo significant verification and validation requirements
to implement this approach. Many laboratories do not have the
volume of specimens or the number of positive specimens that are
received atMayo Clinic. Therefore, a rigorous verification process
is unlikely even at many academic medical centers. An additional
concern is whether the application of BCBs to detect PJIs is con-
sidered a laboratory-developed test (LDT). As an LDT, the FDA
might apply specific regulatory standards that must be met prior
to implementation, which will further limit the potential impact
of this approach.
Beyond the LDT issue, another challenge may be on the hori-
zon for the adoption of this novel culture method. The Center for
Medicare and Medicaid Services (CMS), using data collected by
the National Health Safety Network (NHSN), has established the
Hospital Acquired Condition (HAC) Reduction Program. Hospi-
tals that fall into the lowest quartile of this program face a 1%
reduction of their CMS payments, which means potential loses of
millions of dollars in reimbursements for large health care facili-
ties (9). Current key contributors to this score are central-line-
associated bloodstream infection and catheter-associated urinary
tract infection rates. In fiscal year (FY) 2016, hospital-acquired
Clostridium difficile infection rates will be added. The numbers of
prosthetic joint procedures, many of which are paid for by CMS,
are rapidly increasing. It is generally agreed thatmost PJI areHAC,
with a projected cost by 2020 of 1.62 billion dollars annually (1).
Given the huge amount of dollars at stake, it seems quite feasible
that PJI may become a target of the HAC Reduction Program.
Although the BCBmethod ismore sensitive, in the reported study,
26 patients not meeting IDSA criteria for PJI hadmicroorganisms
isolated from single PPT specimens cultured in BCBs. Particularly
problematic is the observation that organisms that are part of the
skinmicrobiota, coagulase-negative staphylococci, viridans group
streptococci, andPropionibacterium spp.may be found in asmany
as 50% of positive prosthetic joint cultures (1).Most are judged to
be “true pathogens” in this carefully conducted research study,
but will this observation hold true if this method is widely ad-
opted? Will future PJI clinical practice guidelines (3) recommend
BCB culture of PPT as their standard method for detecting PJI
infection, especially since there is not a true microbiologic gold
standard for the diagnosis of these infections? What will be the
NHSN definition of a PJI on which CMS will make their determi-
nation of quality: will it be the standard PPT culture method (2
positive cultures containing skin microbiota organisms such as
coagulase-negative staphylococci, viridans group streptococci,
and Propionibacterium spp. or one positive PPT culture with typ-
ically pathogenic organisms such as Streptococcus aureus and aer-
obic Gram-negative bacilli)? Will BCB monitored by automated
blood culture instruments supplant aerobic and anaerobic plate
and broth cultures for PJI, given FDA scrutiny of LDTs (6–8)?
A final question concerns laboratories being under pressure
fromhospital administratorsworried about the potential financial
impact of increased PJI rates. Will such administrators be leery of
using innovative methods that are off-label applications of FDA-
approved diagnostic devices, such as an automated blood culture
instrument? One potential solution is for automated blood cul-
ture instrument manufacturers to seek FDA approval of novel
applications of their automated blood culture instruments. So far,
manufacturers have been reluctant to do this, with only one com-
pany seeking approval of culture of donated platelets for quality
control purposes. This represents a significant market for BCB
despite the fact that joint, pericardial, pleural, ascites, and perito-
neal dialysis fluids are routinely cultured “off label” in BCB at
many institutions.
This study (6) appears to be a useful and practical advance in
the diagnosis of PJIs. Clinical microbiologists need to be aware of
nonlaboratory issues thatmay have impacts on current and future
laboratory innovation.
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